drugset
drugset / Trial / NCT03318159

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

NCT03318159 ↗

Phase 2 Completed 20 enrolled Seoul National University Hospital Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelPrevention

Summary

To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment

Timeline

Start
2018-04-20
Primary completion
2023-07-15
Completion
2023-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 200 mg —
Subject Posaconazole Small molecule 300 mg —

Indications

aplastic anemia fungal infectious disease myelodysplastic syndrome